A recent analysis found that a significant amount of studies do not provide information pertaining to their raw data, source code or model. As a result, up to 97% of these studies do not produce systems that are fit to be used in real-world clinical scenarios. 

Prior to 2018, it was recommended that women at higher-than-average risk undergo supplemental breast MRI screening only if they had a personal history of breast cancer in addition to carrying a hereditary breast cancer gene mutation.

These notifications can sometimes leave many patients feeling even more bewildered about their mammogram results than they were before being made aware of their dense tissue.

“We must make every effort to grant equitable access to tools that can help individuals and their loved ones treat and manage this disease."

Many patients are unaware of factors that influence how they are billed, such as ancillary fees and organizational setups that use parties offsite to interpret imaging studies. In turn, the pricing information patients receive prior to exams is often incomplete. 

According to data submitted to the FDA, the platform has been linked to an accuracy of 90%, sensitivity of 87.8% and specificity of 83%.

Ed Gaines, JD, vice president of regulatory affairs and industry liaison, Zotec Partners, discussed the impact of the 2023 Medicare Fee Schedule on radiology at RSNA 2022 in Chicago last week. RSNA and several other medical societies say the cuts are not sustainable.

Ed Gaines, JD, CCP, vice president of regulatory affairs and industry liaison, Zotec Partners, discusses the impact of the No Surprises Act on healthcare and medical imaging at the RSNA 2022 meeting